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Ir HDR brachytherapy combined with EBRT at our institution between February




Ir was delivered three times over a period
of 2 days, 6 Gy per time, for a total dose of 18 Gy. Interstitial application was followed by EBRT at a dose of 44 Gy. Progression
was defined as three consecutive prostate-specific antigen (PSA) rises after a nadir according to the American Society for
Therapeutic Radiology and Oncology criteria. The results were classified into those for all patients and for patients who did not




: The 4-year overall survival of all patients, the nonadjuvant hormone therapy group (NAHT) and the adjuvant hormone
therapy group (AHT) was 87.2%, 100%, and 70.1%, respectively. The PSA progression-free survival rate of all patients, NAHT,









 20 groups were 100%, and 46.8%, respectively. According to the T stage classification, PSA progression-free survival
rates of T1c, T2, T3, and T4 were 100%, 82.8%, 100%, and 12.1%, respectively. Prostate-specific antigen progression-free survival








 7 were 92.8% and 60.1%, respectively. Of NAHT, PSA progression-free












 7 was 100% vs






















Prostate-specific antigen (PSA) measurement is now
widely used in screening of prostate cancer, and the disease




 Both hormone therapy and
radical prostatectomy used in the treatment of prostate
cancer have many complications, such as bleeding during
operation, incontinence, anastomotic stenosis of the ure-
thra, and erectile dysfunction. Therefore, it is necessary to
develop new treatment methods that can maintain patients’
quality of life (QOL) as much as possible. Good results
have been reported with the conventional treatment for
localized prostate cancer, radical prostatectomy, which has





this treatment method is associated with a high incidence
of complications, such as incontinence and erectile dys-
function, it remains unsatisfactory from the viewpoint of
postoperative QOL. With regard to radiotherapy, external
radiation using a liniac has generally been performed and
various devices have been developed to improve the results
or minimize complications. However, there are limits to the
effectiveness of external radiation, and the remaining per-
centage of viable cancer cells as determined by prostate





reported that radical prostatectomy is superior to radiation





 whereas recently, good





 Brachytherapy was developed for high-
dose irradiation only to the prostate and to have less effect





HDR brachytherapy has been performed in more than 10
institutions in Japan since 1991. In Kanazawa University





therapy combined with external beam radiation therapy
(EBRT) from February 1999 to December 2003. The
present study was performed to examine the usefulness of
this treatment method.




We evaluated the prognosis and complications during the
follow-up period in the 84 who could be examined of the
97 patients treated with brachytherapy from February 1999
to December 2003. It was impossible to follow up 13
patients because we could not make contact. The patients’
clinical background data are shown in Table 1. Median
patient age was 72 years (range 48–81). Of the 84 patients
included in this study, 35 (42%) were in clinical stage T1c,
30 (36%) were in T2, 12 (14%) were in T3, and 7 (8%)
were in T4. One patient had lymph node (LN) metastasis
and no patients had remote metastasis. Median initial PSA
values were 10.4 ng/mL (range 3.4–251.6) and median ini-
tial prostate volume was 25.0 mL (range 8.9–48.2). Tumors
were classified histologically as adenocarcinomas in all
patients and median Gleason score (GS) was 7 (range 5–
9). Seventy-five (75%) patients underwent neoadjuvant
hormone therapy for 1–18 months.





 exceeded 5%, we recommended lym-
phadenectomy (PLND) to the patient, and 24 (24.7%)
patients underwent PLND. In the event that lymph node
metastasis was confirmed by PLND before brachytherapy,
the patients were excluded from the study. The protocol




 In our institution, we per-
formed the radiation therapy as follows. The radiation




 three fractions) by
brachytherapy. The applicators for brachytherapy were
inserted according to transrectal ultrasound (TRUS) guides
in the lithotomy position under lumbar anesthesia. The
amount of internal irradiation was set to 6 Gy each, and
was performed once on one day and twice on the next day.
Applicators were removed after the third internal irradia-
tion, and then immediately the urethral catheter was tense
for 2 h for the arrest of hemorrhage. The catheter was





fractions) was began from 1–2 weeks after brachytherapy.
Adjuvant hormone therapy (AHT) was performed in
patients who satisfied more than two of the following cri-









Thirty-two patients received AHT and 52 patients did not
receive AHT. Measurement of PSA was performed every
1–3 months after brachytherapy, and digital rectal exami-
nation or TRUS was performed. In the present study, recur-
rence was defined as three times consecutive elevation of
PSA after a nadir, and the day of recurrence was defined
as the day on which the first rise of PSA was observed
according to the criteria of the American Society for Ther-
apeutic Radiology and Oncology (ASTRO).
The results were classified into the all patients group,
patients who underwent AHT, and patients who did not
undergo AHT (NAHT). Kaplan–Meier curve analyses were
used to calculate overall survival and PSA progression-free
survival. Moreover, each group was divided into subgroups
according to initial PSA, clinical stage and GS, and PSA
progression-free survival was also evaluated. The log–rank










Seventy-seven percent of patients received neo-AHT
because many patients were consulted to our hospital after
receiving neo-AHT at other institutions. We investigated
prognosis irrespective of neo-AHT. Although there have
been no previous reports of the effectiveness of neo-AHT,
we thought that performing neo-AHT hardly had an effect
on the PSA progression-free survival after brachytherapy
because most of the prostate cancer tissues provided by





 The median observation period of the 84
patients was 20.4 months (range 1–51). Recurrence of PSA
occurred in 7 of 32 patients (32%) receiving AHT
(Table 1). Of the 52 patients that did not receive AHT, 1
patient had recurrence. Although there was no indication
of when LN metastasis was positive, LN metastasis was
found in one patient in the present study. He was pointed
out about LN metastasis after HDR bachytherapy for reex-
amining LN specimens for another research. The 4-year
overall survival of all patients, the NAHT group, and the









 0.023 between NAHT and AHT). All of the patients
who died were classified as T4 stage, and all received AHT
(Fig. 1). Prostate-specific antigen progression-free survival
of all patients, the NAHT group, and the AHT group was









NAHT and AHT; Fig. 2). The rates according to initial
PSA value are shown in Figure 3. Of all patients, the 4-









 20 group was 46.8%.














 20 showed recurrence, and the PSA progression-




 20 group was 50%. The









 0.019). In the total patient group, PSA progression-












Number of cases 84 52 32
Clinical stage
T1 (n) 35 28 7
T2 (n) 30 23 7
T3 (n) 12 1 11


















7 (n) 39 25 14
AHT, adjuvant hormone therapy; NAHT, nonadjuvant hor-
mone therapy (patients who did not undergo adjuvant hor-
mone therapy); PSA, prostate-specific antigen.




followed), and T4 (40 months followed) were 100%,
82.8%, 100%, and 12.1%, respectively (Fig. 4). In the
NAHT group, the rates for T1c and T2 were 100% and
75%, respectively. The rates classified according to GS are
shown in Figure 5. Of all patients, PSA progression-free




 7 group was 92.8%, which was





(60.1%). The NAHT group showed the almost same result
as all patients.
The complications are shown in Table 2. No significant




Kaplan–Meier analysis of overall survival. Percent of
overall survival of the patients in all patients, nonadjuvant







































Kaplan–Meier plot of prostate-specific antigen (PSA)
progression-free survival. Percent of PSA progression-free
survival of the patients in all patients, nonadjuvant hormone
therapy group and adjuvant hormone therapy group was com-










































Kaplan–Meier plots of progression-free survival
according to initial prostate-specific antigen (PSA). For both
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urgent treatment occurred, except in one patient with prior
atrial fibrillation and a cerebral infarction that had
occurred 6 months previously merged with cerebellar in-
farction during the treatment described here. The most
common complication was urination trouble (8.2%) such
as dysuria and urinary retention. The incidence of inconti-
nence was 4 of 97 cases (4.1%). Two cases (2.1%) needed
transfusion by bleeding from the prostate after removing
the applicators. Although a in one case, perforating the
peritoneum caused the blood pressure to fall, the patient
felt better after sufficient infusion and receiving catechola-





Kaplan–Meier plots of progression-free survival
according to clinical stage. There was no significant difference
between T1 cases and T2 cases in all patients and nonadjuvant
hormone therapy groups. N.S., not significantly different.
All patients








































































Kaplan–Meier plots of prostate-specific antigen
(PSA) progression-free survival according to Gleason score


























































































HDR brachytherapy-boosted EBRT. Although the observa-
tion period was short,  PSA recurrence was observed in
8 of 84 patients; 6 of these cases were classified as T4.
Risk factors before radiotherapy for PSA-free survival





 Especially, PSA progression-free survival rate








 20 cases. We also inves-
tigated the NAHT group to exclude effect of hormone
therapy. As we expected, these rates in the NAHT group
were very good during the 4-year follow-up period. The





 performed according to a protocol sim-
ilar to our institution, was reported 67%. However, further
longer-term follow up is still necessary.
Since AHT eventually affects the prognosis of patients,
we classified the patients by presence of AHT and com-
pared prognosis. We gave AHT to the high risk patients
who satisfied more than two of the following criteria: stage








 20 ng/mL in order to make
risk of recurrence lower. We gave AHT to 38% of patients
in the present study. We expected AHT to improve the
patients prognosis. However, the PSA progression-free sur-
vival rate in the AHT group was still poor. The reason for
this result was especially due to the performance to the
patients with stage IV disease, and local-relapsed patients
after hormone therapy. In fact, the high risk patients who
were treated with AHT except stage IV and local-relapsed
patients still have good prognosis for 2 years after brachy-
therapy (Fig. 4). Combination of brachytherapy and AHT
for high risk patients might improve the prognosis.
Complications of brachytherapy such as incontinence
are relatively infrequent as compared with radical prostate-
ctomy. The most common complication was urinary reten-







-blocker and/or detaining the urethral cath-
eter for a short term, and there were no cases in which QOL
was decreased for a long time. The main cause of dysuria
was thought to be that the applicators passed near an ure-
thra, the urethral around was enlarged, and an urethra was
suppressed when we implanted applicators into the pros-
tate. In particular, these complications occurred mainly in
the early period of this therapy. Then we diminished these
complications in therapeutic anaphase by devising a
method of implant. The cases of incontinence have been
treated by medication of anticholinergic drugs, and all were
slight. In the case of peritoneal perforation, we used appli-
cators of conventional length and penetrated the bladder,
and perforated the peritoneum due to the short height of
the patient. We believe this complication could be avoided
by doing puncture while considering the height of the
patient more carefully.




Ir HDR brachytherapy is as
effective and as radical prostatectomy and a less invasive
form of therapy for prostate cancer. Moreover, it is
expected to be associated with marked improvements in
patients’ QOL in the perioperative period. Now we are
investigating it with regard to long-term complications
such as erectile dysfunction, incontinence, and diarrhea.
Since the initial report of seeding according to TRUS
by Holm, brachytherapy has become one of the main meth-
ods used for treatment of prostate cancer because of its





 Now, permanent seeding brachytherapy for
prostate cancer is the most common form in the United




I prostate implants were
approved for clinical use in July 2003, and therapy using
such implants has recently been performed in some insti-
tutions. As it is much less invasive than HDR brachyther-
apy and is possible to apply on a day-surgery basis, it is
expected to become the standard method of brachytherapy
































I seeding showed good tumor control for small
tumors with good differentiation, but that this source is not





 On the other hand it is thought that HDR
brachytherapy is effective for prostate cancer discovered
after TUR-P and local advanced prostate cancer by devised
insertion of applicators to seminal vesicle and so on. Fur-
thermore, we think that combining AHT can raise curative
effect for local advanced cancer. Compared to seeding
therapy, HDR brachytherapy has strong antineoplastic









Ir was an alternative treatment





 They reported that progression-free survival for
clinical stage T3 patients was 65% at 5-year follow up.
Moreover, local control of clinical T3 tumors was reported









I prostate implants have been intro-





Ir HDR brachytherapy as a possible treatment













The major complications in the treatment are
indicated
Complication Number of cases
Urinary retention 8 (9.5%)
Incontinence 4 (4.8%)
Blood transfusion 2 (2.4%)
Ileus 1 (1.2%)
Delirium 1 (1.2%)
Cerebellum infarction 1 (1.2%)
Perforating peritoneum 1 (1.2%)
No significant intraoperative or postoperative complica-
tions requiring urgent treatment occurred except cerebellum
infarction.
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tion period was short, brachytherapy appeared to be as
effective as radical prostatectomy, but with comparatively
few complications. Moreover, we think that it is still more
effective to carry out combined HDR brachytherapy and


















 Cancer control with














external beam radiation therapy for adenocarcinoma of the
prostate: correlation with original histological grade and














 Long-term results of
a randomized trial for the treatment of Stages B2 and C
prostate cancer: radical prostatectomy versus external beam
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guided high dose rate conformal brachytherapy boost in
prostate cancer: treatment description and preliminary
results of a phase I/II clinical trial. 
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